NCT06195267 Protective Effect of Sivelestat Against Negative Pulmonary Function and Organ Dysfunction After Cardiovascular Surgery (PANDA VI)
| NCT ID | NCT06195267 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Nanjing Medical University |
| Condition | Aortic Dissection |
| Study Type | INTERVENTIONAL |
| Enrollment | 500 participants |
| Start Date | 2024-07-01 |
| Primary Completion | 2025-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 500 participants in total. It began in 2024-07-01 with a primary completion date of 2025-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Systemic inflammatory response syndrome (SIRS) and multiple organ dysfunction syndrome (MODS) are the major causes of death in patients with cardiovascular diseases. Therefore, the prevention of SIRS and MODS is of great clinical value, and immunomodulatory therapy with sivelestat may be beneficial. This study was designed to test the hypothesis that the administration of sivelestat during the acute phase of cardiovascular diseases will result in a reduced incidence of SIRS and MODS.
Eligibility Criteria
Inclusion Criteria: * The patients are conformed to 2010 ACC/AHA guidelines for the diagnosis and treatment of thoracic aortic disease (TAD) within two weeks of onset; * Patients with type A acute aortic syndrome confirmed clinically and radiologically and planning to undergo emergency surgery were enrolled. * The patients' age between 18 \~90 years old. * Agree to participate in the study and sign the informed consent. Exclusion Criteria: * Patients allergic to sivelestat sodium; * Lactating women and pregnant women; * Patients with mental diseases, drug and alcohol dependence; * Refuse to participate in this study and refuse to sign the informed consent.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06195267 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 90 Years, studying Aortic Dissection. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06195267 currently recruiting?
Yes, NCT06195267 is actively recruiting participants. Contact the research team at dr.hongliu@foxmail.com for enrollment information.
Where is the NCT06195267 trial being conducted?
This trial is being conducted at Beijing, China, Nanjing, China.
Who is sponsoring the NCT06195267 clinical trial?
NCT06195267 is sponsored by Nanjing Medical University. The trial plans to enroll 500 participants.